The Latest

  • Lilly Biotechnology Center in San Diego, California
    Image attribution tooltip
    Michael Vi / Getty Images via Getty Images
    Image attribution tooltip
    Q&A

    How Lilly’s sustainability goals come face to face with massive growth

    Eli Lilly’s head of ESG is maintaining a focus on sustainability even as the company’s expansion plans in weight loss drive a larger footprint and more social scrutiny.

  • Charlotte Owens
    Image attribution tooltip
    Permission granted by Organon
    Image attribution tooltip

    Why pharma should redefine ‘women’s health’

    A broader approach recognizes the challenges disproportionately impacting women and could lead to better outcomes, according to Organon. 

  • Sanofi and Regeneron's Dupixent
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip

    3 FDA approval dates to watch in the year’s final push

    A handful of potential blockbusters are marching toward FDA review.

  • Pharmaceutical cartons with the logo for Bristol Myers Squibb's Opdivo rest on a refrigerator shelf.
    Image attribution tooltip

    George Frey/Reuters

    Image attribution tooltip
    Deep Dive

    A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

    Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

  • Drug money
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    A new way of determining a drug’s value — with health equity in mind

    Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health. 

  • A flag flies above the headquarters campus of Eli Lilly
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies

    The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.

  • Brain disorder
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Huntington’s disease R&D is regaining ground after several disappointments

    Setbacks haven’t stopped advances by biotechs and pharmas working on new drugs for the inherited brain disorder.

  • layoff concept
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    What 3 layoff stories reveal about pharma’s troubles

    The factors driving the industry’s layoffs — and what could help turn the tide.

  • Cristal Downing, chief communications and public affairs officer, executive vice president, Merck & Co.
    Image attribution tooltip
    Permission granted by Merck & Co.
    Image attribution tooltip

    Big Pharma is often media shy. Merck’s chief comms officer is hoping to change that.

    Cristal Downing is helping Merck & Co. buck pharma’s zipped-lip status quo and usher in a “new era” of openness, transparency and “overt communication.”

  • lab pink liquid
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s ‘it’ therapy — a new drug class gaining steam

    More companies are investing in protein degraders, which leverage a unique approach to harnessing the immune system in cancer, neurological diseases and more.

  • Pfizer HQ entrance
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip

    A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market

    Results from Vaxcyte’s clinical pneumococcal vaccine study showed the smaller company could take on Pfizer’s legendary blockbuster.

  • Front sign of FDA building
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA adcomm reform talks heat up

    As the agency considers eliminating adcomm votes from the approval process, members vie to have their voices heard.

  • test tube dollar
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Is anyone taking the world’s priciest drugs?

    A slew of breakthrough gene therapies won FDA approval in recent years — but high price tags haven’t always yielded big returns.

  • Wall Street buildings
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Their Alzheimer’s treatment worked — but shares fell anyway

    Cognition Therapeutics touted what the C-suite saw as a promising mid-stage study in Alzheimer’s, but investors read a different story.

  • gloved hands cutting psilocybin mushrooms growing in a container
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After an FDA rejection, here’s what’s next in the psychedelics pipeline

    By rejecting the first MDMA therapy earlier this month, the FDA signaled to the psychedelic drug sector that the road to approval isn’t clear cut.

  • AI hallucination medical
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk

    While AI, machine learning and large language models can distill huge amounts of information, they sometimes make mistakes. New technologies could rebuild that trust.

  • Dr. PK Morrow headshot
    Image attribution tooltip
    Permission granted by Takeda Pharmaceuticals
    Image attribution tooltip
    Q&A // First 90 Days

    With a new oncology R&D head, Takeda revamps its strategy

    The company is using a “three-by-four” approach to sharpen its cancer R&D aims.

  • An exterior view of a court house.
    Image attribution tooltip
    PierreDesrosiers via Getty Images
    Image attribution tooltip

    Pharmas’ IRA court losses mount. They keep pursuing them.

    The final drug prices for Medicare’s negotiation program have been published, but pharma companies continue to push their legal strategies.

  • mpox vaccine
    Image attribution tooltip
    Mario Tama/ via Getty Images
    Image attribution tooltip

    As a new mpox strain gains ground, a key drug stumbles in the clinic

    Despite the disappointing results, the drug’s developer, Siga Therapeutics, said there’s more to the story.

  • Dr. Reed Tuckson, founder, Black Coalition Against COVID
    Image attribution tooltip
    Permission granted by Reed Tuckson
    Image attribution tooltip

    Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through

    A long-time leader in public health and outreach to people of color, Dr. Reed Tuckson offers the lessons he learned from the COVID pandemic and how pharma can better serve those communities.

  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    BioMarin taps Amgen, Roche vets in executive reshuffle

    Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.

  • Pill drug money balance
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Will the IRA squash new drugs? Those worries are likely exaggerated, studies say.

    There’s no link between revenue and R&D from smaller biotechs, and that’s where most innovation comes from, according to new studies.

  • Supreme Court building illuminated at night
    Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip

    Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision

    The Supreme Court case added another layer of uncertainty on the regulatory front and opened up the Inflation Reduction Act to more legal attacks.

  • Image attribution tooltip
    Courtesy of 23andMe
    Image attribution tooltip
    Q&A

    23andMe inches closer to cancer immunotherapy, guided by its genetic database

    Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.

  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Novo plans new plant as it races to meet drug demand

    The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.